What podcasts say about Chef Station
Every statement, with the speaker, the exact quote and the moment it was said.
What Chef Station has said on podcasts
16 statements · 11 positive · 1 negative · 1 mixed · 3 neutral
FDA leadership changes could occur in 2027
“2027 could be the year that we see this change with the FDA”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 6:44
Aldeyra should submit its FDA dispute resolution soon
“we should hear. you know, in the next week or so that they've actually submitted this”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 14:14
Aldeyra could receive approval in early January
“we're probably looking at early January for them to get approved”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 16:25
Chef views Aldeyra’s current position favorably
“I really like where the company is at right now”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 16:48
Inovio appears well positioned ahead of its FDA decision
“they look like they're in good standing”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 19:08
Inovio could rise around its October FDA decision
“we might start to see that one really pop up”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 20:37
Chef sees Unicycive’s potential inspection outcome as an opportunity
“I think it'll be a great opportunity”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 25:50
Additional weight loss with Vivani’s implant could materially benefit the company
“If weight loss is shown in addition to using Wagovi or semaglutide, it's going to be big for the company”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 28:35
Fractyl Health’s pivotal cohort data should arrive soon
“data should be in the next week or two”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 32:24
OsteoVax could receive accelerated approval in December
“if they get accelerated approval in December”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 33:24
OsteoVax could sell its priority review voucher for $200–250 million
“which they can sell for 200 to 250 million”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 33:34
Pasithea Therapeutics’ stock has recently declined
“that stock has been getting hit”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 35:08
Kineta’s fourth-quarter data could materially affect the company
“they've got data in the fourth quarter that could be significant for the company”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 38:02
Ovid’s OV329 data will be reported at year end
“that data is going to be year end readout”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 38:52
Gossamer’s NDA acceptance could occur around November 27
“it should be around November 27th because it's usually 60 days from when they send it out”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 41:26
Gossamer’s financing suggests investors expect no refuse-to-file decision
“I think obviously with this, you know. The structured financing investors and institutions are pretty confident that that's not going to happen”
Open the episode · Biotech Stocks to Watch: FDA Shakeups, ESMO Data & Late 2026 Biotech Catalysts Sheff Is WatchingListen at 42:55
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.